A

AmyPore

10 employees

AmyPore develops an innovative drug that targets a common mechanism of Alzheimer's and Parkinson's diseases.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Pharmaceutical
type 2 diabetes
amyloid pores
cholesterol
gangliosides
neurodegenerative diseases
molecular dynamics simulations
calcium imaging
molecular neurosciences
Health Care
biological membranes
drug design
lipid rafts
amyloid oligomers
lipid-protein interactions

Date founded

2018

Funding rounds raised

Total raised

$82K

from 2 investors over 2 rounds

A

AmyPore raised undisclosed on April 3, 2019

Investors: Incubateur inter-universitaire Impulse

A

AmyPore raised $82K on January 1, 2019

Investors: Executive Agency for Small and Medium-sized Enterprises (EASME)

FAQ